Resmed

Narval™ CC



Narval CC

A clinical proven option for long-term adherence[1]

Obstructive Sleep Apnoea : a growing clinical challenge[2]

Among adults aged 30-69 in the EU, OSA **prevalence (AHI>5) is projected to increase from 33,1% in 2020 to 52,3% by 2050**, driven by ageing populations and rising cardiometabolic risk factors[2].

1 in 5 adults[3]
affected by OSA worlwide

Yet too many patients remain without an effective long-term solution

Despite CPAP being the golden standard[4], nearly **50% of patients discontinue CPAP within 3 years**[5].

Yet fewers than 1% of these patients transition to an oral appliance afterwards[5].

~50%
CPAP discontinuation
within 3 years[5]

<1%
transition to oral appliances[5]

When OSA is left untreated, risks rise fast

Untreated OSA contributes to increased cardiovascular, metabolic, cognitive and safety risks. Ensuring patients receive and maintain effective therapy is essential to reducing this burden.



x3
higher risk of being involved in a road accident[6]



x3
greater risk of cardiovascular events[7]



x3
higher likelihood of developing high blood pressure as a secondary condition[8]



x5
higher probability of cardiac complications[9]

MAD : recommended by international guidelines[1,4,10]

International guidelines position oral appliance therapy as an effective treatment option for OSA.

What guidelines say in practice

- ✓ Mild to moderate OSA : first line
- ✓ CPAP intolerance : recommended alternative

Both the **American Association of Dental Sleep Medicine** (AADSM) and **European Respiratory Society** (ERS) recommend that sleep physicians consider prescription of oral appliances, rather than no treatment :

- ✓ For adult patients with OSA who are intolerant of CPAP therapy or prefer alternate therapy[10].
- ✓ For adult patients with mild to moderate OSA[11].
- ✓ For adult patients who request treatment of primary snoring (without OSA)[10].

Mechanism at a glance

Narval CC uses a traction-based mechanism to advance the mandible, helping keep the airway open during sleep and reduce apnoeas and snoring while maintaining comfort.

Narval CC

- ✓ Keeps airways open by drawing the lower jaw forward
- ✓ Reduces soft tissue vibration to minimise snoring
- ✓ Improves oxygenation and restores restorative sleep cycles

Healthy patient
(airway open)



Patient with untreated snoring
(airway partially closed)



Patient with untreated OSA
(airway closed - apnoea)



Patient treated
(with Narval CC appliance)



Robust clinical results, confirmed at 5 years[12]

Narval CC : High efficacy on AHI

Narval CC has proven to be an effective solution to treat OSA on both short-term[1;13] and long-term[12] follow up, with good tolerability and compliance. These results were demonstrated during the largest prospective cohort study[1] ever performed on mild to severe OSA patients treated with MAD.

Custom-made MAD: effective across mild to severe OSA[1]





Fig. 2: Efficacy of treatment by type of MAD at 3-6 month follow-up.

Good efficacy at 5-year follow-up




Treatment was particularly effective in the severe OSA group : 63% of severe OSA patients achieved a reduction in AHI >50% at 5 years[12].

Comparable effectiveness of oral appliance and CPAP[14]

Head-to-head trials confirm that CPAP is superior to MAD in reducing OSA parameters on polysomnography. However, this greater efficacy does not necessarily translate into better health outcomes in clinical practice.

Comparable effectiveness of MAD and CPAP has been attributed to higher reported nightly use of MAD, suggesting that inferiority in reducing apnoeic events may be counteracted by greater treatment adherence.



When tolerance limits the effectiveness of CPAP: Narval CC can be a solution[12].



Long-term adherence results make Narval CC a validated alternative, when CPAP is refused or not tolerated[12].

6
hours/night usage on average at 5-years follow up[12]

97%
of patients want to continue therapy at 2-years follow up[13]

Narval CC : a solution that patients actually **continue to use**

83%
of patients continued using the device nightly after 5 years[12]

9%
dropout due to side effects after 5 year follow-up[13]


Narval CC precision-engineered for comfort and results

Made in France



Customization : a choice of 5 designs for personalization

VESTIBULAR – FACIAL BAND



INCISOR FULL COVERAGE




PALATAL/LINGUAL BAND



FACIAL BAND *WITH CAP*



PALATAL/LINGUAL BAND *WITH CAP*



Why Narval CC is different

Custom-made
to each patient's dental anatomy and clinical profile


Thin, light, biocompatible
design for long-term comfort[1]

Patented traction articulation
that reduces TMJ stress by 10% vs compression devices[15]

Simple titration
for precise mandibular adjustment
Rods are available in different sizes to follow or maintain lateral deviation.

myNarval : turning invisible progress into tangible insighs

Resmed complements Narval CC with digital tools designed to **support patient engagement**.



myNarval is designed to helps patients stay involved in their therapy journey.

with myNarval, your patients can

- Visualize their progress (wearing the O2 ring)
- Receive tailored tips and reminders by email or SMS
- Capture how they feel in their sleep journal

Patients can choose to **share a summary report (PDF)** with their healthcare professional to support ongoing discussions about treatment follow-up.

The sleep prescriber :
leading the path to **better sleep health**[1]

As the cornerstone of OSA management, the sleep prescriber identifies the right candidates and sets the treatment plan in motion.
By partnering with trained Narval dentists, you can help each patient to recieve a personalized and comfortable therapy. Your clinical expertise can turn prescription into long-term success, helping more patients breathe, sleep, and live better.

myNarval is not a medical device.
PROMOTIONAL MATERIAL - Narval CC is compliant with applicable regulations. Manufacturer: Resmed.
Pulse Oxymeter O2 ring is a CE-marked medical device (CE NB0197). Manufacturer: Shenzhen Viatom Technology Co., Ltd.
Local contact: Resmed. Please refer to the instructions for use for relevant information related to any contraindications, warnings and precautions.
This content is intended for health professionals only.

1.Vecchierini MF et al. A custom-made mandibular advancement device for obstructive sleep apnoea-hypopnoea syndrome: the ORCADES study. Sleep Medicine 2016 Mar; 19:131-40. *A 5-year prospective observational multicentre cohort study on 331 OSA patients. 3-6 months follow-up data analysis. Clinical Trials.gov identifier: NCT01326143.
2.Boers E, Kaye L, Malhotra A, et al. Projecting the future burden of OSA in EU5 countries accounting for body mass index. European Respiratory Journal. 2025;66(Suppl 69):OA4354. doi:10.1183/13993003.congress-2025.OA4354.
3.Benjafield, Adam V et al.Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. The Lancet Respiratory Medicine, Volume 7, Issue 8, 687 – 698
4.Randerath and al., European Respiratory Society guideline on non-CPAP therapies for obstructive sleep apnoea. European Respiratory Review 2021 30(162): 210200; DOI: https://doi.org/10.1183/16000617.0200-2021
5.Pépin, J.-L.; Bailly, S.; Rinder, P.; Adler, D.; Szeftel, D.; Malhotra, A.; Cistulli, P.A.; Benjafield, A.; Lavergne, F.; Josseran, A.; et al. CPAP Therapy Termination Rates by OSA Phenotype: A French Nationwide Database Analysis. J. Clin. Med.2021, 10, 936. https://doi.org/10.3390/jcm10050936
Retrospective analysis on 480 000 adult patients with CPAP therapy initiated from 2015 to end of 2016, identified in the French Health insurance claims database, and followed up until end of 2019
6.Ellen et al. Systematic review of motor vehicle crash risk in persons with sleep apnea. J Clin Sleep Med. 2006 Apr 15;2(2):193-200.
7.Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005 ; 365 : 1046-53.
8.Peepard T. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 342 (2000), pp. 1378-1384.
9.Peker Y, Carlson J, Hedner J. Increased incidence of coronary artery disease in sleep apnoea: a long-term follow-up. Eur Respir J. 2006 Sep;28(3):596-602.
10.Ramar K et al. Clinical practice guideline for the treatment of obstructive sleep apnea and snoring with oral appliance therapy: An update for 2015. Sleep Medicine 2015;11(7):773-793. (AADSM recommendations).
11.Marklund M et al. Non-CPAP therapies in obstructive sleep apnoea: mandibular advancement device therapy. European Respiratory Journal 2012 39: 1241-1247. Based on the ERS Task Force Report on MAD therapy.
12.Vecchierini MF, Attali V, Collet JM, et al. Mandibular advancement device use in obstructive sleep apnea: ORCADES study 5-year follow-up data. J Clin Sleep Med. 2021;17(8):1695-1705. doi:10.5664/jcsm.9308.
*A 5-year prospective observational multicentre cohort study on 331 OSA patients. 5-year follow-up data analysis. Clinical Trials.gov identifier: NCT01326143.
13.Attali V et al. Efficacy and tolerability of a custom-made Narval mandibular advancement device for the treatment of obstructive sleep apnea: ORCADES study 2-year follow-up data. Sleep Med. 2019 Nov; 63:64-74. * A 5-year prospective observational multicentre cohort study on 331 OSA patients. 2-year follow-up data analysis. Clinical Trials.gov identifier: NCT01326143
14.Sutherland et al. Efficacy versus Effectiveness in the Treatment of Obstructive Sleep Apnea: CPAP and Oral Appliances. Journal Dental Sleep Medicine, 2015.
15.Cheze et al. Impact on temporomandibular joint of two mandibular advancement device designs. ITBM-RBM, Volume 27, Issues 5–6, November–December 2006, 233- 237. Computer-simulated biomechanical study.

a. to date (March 2026)
b. Success rate = % of patient with an AHI reduction >50%

Resmed SAS
Parc Technologique de Lyon
292 allée Jacques Monod
69791 Saint-Priest Cedex France

Narval CC is a trademark of Resmed SAS.
See www.resmed.com for other ResMed locations worldwide.
© 2025 Resmed Ltd. 10114625/1 ENG 06/2026